

# THE LANCET

## **Supplementary webappendix**

This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors.

Supplement to: Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials. *Lancet* 2011; published online Aug 1. DOI:10.1016/S0140-6736(11)60872-6.

**Effect modification by population dietary folate on the association between *MTHFR* genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials**

## **Supplementary materials**

### **Methods**

#### ***Search Strategy***

##### *Randomised clinical trials*

For MEDLINE, the Mesh terms “cardiovascular disease”, “coronary heart disease”, “coronary stenosis”, “myocardial infarction”, “cerebrovascular accident”, “stroke”, and “randomised controlled trial”, “clinical trial”, and “folic acid” were utilised. We also searched for trials published only as an abstract in conferences or meetings<sup>1</sup> as well as in previously published meta-analyses addressing this question<sup>2,3</sup>.

For inclusion in the analysis, studies had to: (i) be randomised and parallel in design; (ii) be conducted in adults; (iii) examine the effects of folic acid supplementation (with or without additional vitamin B supplementation); (iv) record stroke as an outcome, and; (v) have 12 months minimum follow-up. Studies using folic acid combined with a multivitamin/mineral tablet versus placebo/standard care were excluded<sup>4</sup>.

##### *Genetic studies*

We used the text words, which were also MeSH terms, “polymorphism”, “mutation”, “genotype”, “genetic”, “gene(s)”, “allele(s)” in combination with “stroke”, “cerebrovascular disorder/disease”, “cerebral ischemia”, “hemorrhagic stroke”, “(silent) brain infarction”. Literature searches were limited to “human”. All languages were included. Additional studies in the references of all identified publications, including previous relevant meta-analyses were identified.

In the analysis of the *MTHFR/C677T* variant on Hcy levels, studies were included if the design was case-control, cohort or cross-sectional. For inclusion in the analysis of *MTHFR/C677T* variant and stroke, case-control, cohort, or cross-sectional studies evaluating ischaemic, haemorrhagic or undifferentiated stroke were included. In all searches, when relevant information was not reported or there was doubt about duplicate publications, we contacted authors for clarification.

We supplemented information from published studies with unpublished genetic data obtained through direct contact with investigators of any study that had previously reported at least one genetic finding in stroke (for case-control studies) or in cardiovascular disease (for cohorts) in a peer reviewed journal. This allowed us to minimise the scope for reporting and publication bias. A total of 52 investigators of newly identified studies were asked to provide the most up-to-date information on the *MTHFR/C677T* variant and stroke risk in the form of genotype counts by disease status (cases [ischaemic, hemorrhagic or undifferentiated stroke] and controls) and the average values of Hcy and

folic acid by *MTHFR*/C677T genotypes in subjects without cardiovascular disease. Authors of 44 studies replied and provided information.

### **Data extraction**

#### *Randomised trials*

For randomised trials, the following variables were extracted (by MVH and JPC, **see eTable 5**): study design, patient characteristics, calendar years in which trial conducted; geographical region; type of stroke outcome(s) recorded; mean follow-up period, and; type of intervention(s) used as comparator (usual care, placebo, lower-dose folic acid, B vitamin alone). In addition, in each arm we recorded: (a) number of participants; (b) number of stroke events; (c) baseline and post-intervention levels of Hcy (where applicable), and; (d) doses of intervention(s) used. To determine the risk of bias, we evaluated: (i) sequence generation; (ii) allocation concealment; (iii) incomplete outcome data, and; (iv) selective outcome reporting, as suggested by the Cochrane Handbook for Systematic Reviews of Interventions<sup>5</sup>. Disagreements were resolved by consensus.

For each trial, point estimates of relative risk with 95% confidence intervals were derived using values of outcome events in each study arm. For all studies, we used intention to treat analysis. In cases of discrepancy or doubt about the number of events (stroke/TIA), we contacted authors to clarify details. Outcomes were recorded separately for (i) stroke, excluding TIA, and, (ii) stroke including TIA with comparator arms classified as (i) placebo, B-vitamins and/or folic acid [where folic acid in the comparator arm was low-dose compared to the intervention arm], and (ii) placebo only, excluding studies in which no placebo or usual care was used (i.e. Wrone<sup>6</sup> and Toole<sup>7</sup>), or events in participants randomised to vitamin B6 as one of three arms (i.e. Ebbing<sup>8</sup> and Bonaa<sup>9</sup>). To increase comparability of RCTs with genetic studies, we selected only stroke events excluding TIA as the main outcome and compared intervention with any of placebo, vitamin B and/or (low-dose) folic acid.

#### *Genetic studies*

For genetic studies the following variables were extracted (by PN and MVH, **see eTable 1 and 2**): study design, participant characteristics, country and calendar year in which the study was conducted, study design, proportion of males, mean age of participants, frequency of genotypes and alleles by case control status, average value (mean, median) and measure of dispersion (standard deviation, standard error, confidence interval, inter-quartile range or range) of Hcy and folic acid concentrations, stroke sub-type(s), language of publication, and ethnic background. We also calculated Hardy-Weinberg equilibriums (HWE) and disequilibrium coefficients for all genetic studies: in studies of *MTHFR*-stroke, only allele frequencies in controls were used; in *MTHFR*-homocysteine studies, allele frequencies of all participants were used. Where the number of subjects per genotype was selected/restricted *a priori* by the study investigators, HWE values were not estimated. For plots of allele frequency, we categorized studies into (i) probable folate status category, and (ii) ethnicity.

Ethnicity was classified according to the subjects investigated: studies or study subsets were categorized as follows: (i) Caucasian: including Israel and Turkey; (ii) African; (iii) East Asia including individuals from Japan, China, Korea, Hong Kong and Mongolia; (iv) South Asia including India, Pakistan and Bangladesh; (v) Latin America, and; (vii) mixed ethnicity. Plots were restricted to those studies that had values for all 3 genotypes and/or had not selected the number of subjects per genotype status.

### ***Categorization of genetic studies by probable folate status***

These categories (developed and validated by Dr Robert Clarke, Clinical Trial Service Unit (CTSU) and Epidemiological Studies Unit, University of Oxford, UK) used information on geographical location and dates during which the genetic study was conducted. and considered: (i) whether policies for folic acid fortification had been initiated and the date of implementation, and; (ii) whether there had been a change in folic acid levels at population levels through time. This information was derived from population based studies with information on folic acid. Geographical regions served as proxies of folate supplementation status. Categories were sorted according to the level of folic supplementation from the lowest to the highest as follows. (1) **Asia**: in addition to Asian countries (e.g. China, India, Hong Kong, Korea, Thailand, Mongolia) this category also included countries from North and sub-Saharan Africa conducted at any time. (2) **Europe-low** (pre-fortification): including studies from Ireland, Scandinavia (Denmark, Norway, Sweden, Finland), Netherlands, Russia and Turkey conducted at any time, and European countries conducted prior to folic acid fortification of cereal and flour, initiated in 1996. (3) **Europe mid** (post-fortification): including all European countries in 1996 or thereafter (except Ireland, Scandinavia, Netherlands, Russia or Turkey). (4) **America & Australia & New Zealand mid** (pre-fortification): which included studies from North-America, Australia and New Zealand prior to 1996, and studies from Central and South America conducted at any time, except for Chile, in which only studies conducted prior to 2000 were classified in this category. (5) **America & Australia & New Zealand high** (post-fortification): which included studies from North-America, Australia and New Zealand conducted in 1996 and thereafter, and studies conducted in Chile in 2000 and thereafter. For 67 studies (of 137) on which information was unavailable (from the publication, or previous publications from the same study, or after contacting study authors) on the timing of the study, 2-years prior to the publication date was used as the year the study was conducted. This value (median) was derived from the 70 studies that provided information on time of study conducted and year of publication. Information on the categories allocated to each genetic dataset included in the analysis is described in **eTables 1 and 2**.

### ***Data Analysis***

All meta analyses were performed using the 'metan' command<sup>10</sup> in Stata (StataCorp, Texas, USA) version 11.1. For meta-analysis of genetic association studies, we followed guidance from the Human Genome Epidemiology Network (HuGENet) HuGE Review Handbook<sup>11</sup>.

### *MTHFR and homocysteine level*

The estimate of the mean difference was restricted to individuals without clinical evidence of cardiovascular disease (ischaemic heart disease, stroke, or venous thrombosis). In order to explore the modifying effect of folic acid levels on the *MTHFR/C677T*-Hcy association, two strategies were utilized. First, we conducted a stratified meta analysis of the effect of the *MTHFR/C677T* variant on Hcy levels according to the 'probable folate categories'. Second, we performed a meta-regression analysis of the difference in Hcy levels by genotype against the average concentration of folic acid in each study. Analyses were then repeated only in studies with sample size  $\geq 500$  individuals in order to explore the influence of small-study bias in addition to funnel plot and Egger regression tests<sup>12</sup>.

### *MTHFR and Stroke*

The outcome 'main stroke comparison' was used to make comparisons with results from RCTs of Hcy lowering therapies. The 'main stroke comparison' included studies reporting: (i) only-ischaemic stroke, (ii) only-haemorrhagic stroke, (iii) both (ischaemic and haemorrhagic separately) stroke, or (iv) only unclassified stroke (studies in which neuroimaging tools were not available to classify the event as haemorrhagic or ischaemic). For studies reporting ischaemic and/or haemorrhagic stroke, diagnosis was by neuroimaging (MRI or CT). For this meta-analysis, we assumed equivalence between risk ratio and OR. We used the probable folate status categories to explore whether the *MTHFR/C677T* effect on stroke was modified by folic acid levels in a meta-regression. For studies with information on Hcy levels and stroke, the effect of the *MTHFR/C677T* variant on stroke was stratified according to the difference in Hcy levels (in tertiles) determined by the genetic variant.

### *Evaluation of small study bias*

To evaluate the potential influence of small-study bias on risk of stroke (*MTHFR* TT vs CC) in Asia, we first restricted the analysis to large studies with  $\geq 400$  stroke events. Second, we performed Egger regression tests<sup>12</sup>, which tests the null hypothesis that the funnel plot is symmetrical. Third, we implemented Duval and Tweedie's 'trim and fill' method<sup>13</sup> using the 'metatrim' command in Stata<sup>14</sup>. This method uses the observed asymmetry in the funnel plot to estimate the number and outcomes of missing studies, and adjusts the meta-analysis to incorporate missing data. Fourth, we generated a hypothetical study with 400 cases distributed evenly to CC and TT genotype groups according to a TT frequency of 15% (derived from HapMap values obtained at dbSNP; [www.ncbi.nlm.nih.gov/projects/SNP](http://www.ncbi.nlm.nih.gov/projects/SNP)) for genotype frequencies in Asian populations). We sequentially added the hypothetical studies and the used cumulative meta-analysis to estimate the number of such studies that would have to exist to:

- (a) reduce the point estimate to 1.15; the threshold at which evidence for a genetic association is downgraded based on the Venice criteria<sup>15</sup>;
- (b) reduce the point estimate to 1.10 (comparable to an expected relative risk reduction of 10% in an RCT of a Hcy lowering intervention), a threshold below which the sample size of a trial of a Hcy-lowering intervention on stroke risk might become too large to be considered practical;
- (c) reduce the lower bound of the 95%CI to 1.00.

Finally, we compared the number of large studies ( $\geq 400$  stroke cases) from Asia (low-folate region) category with other geographical regions.

Although Mendelian randomisation studies minimise confounding by environmental factors that may confound the blood marker-disease association, they can still suffer from confounding by linkage disequilibrium (LD). This is particularly relevant since in recent years, genome wide association studies have identified hits for established cardiovascular risk factors such as blood pressure, among those a variant (rs17367504) within the *MTHFR* gene<sup>16</sup>. In addition, since we included studies from different genetic ancestries, it might be possible that a different set of correlations (LD) of the rs1801133 variant occurs amongst different ethnic groups (e.g. Asians vs. Europeans), which therefore could confound our analyses. To explore this, we used the GLIDERS software<sup>17</sup> to evaluate long range LD for the rs1801133 variant among the main ethnic groups and cross-checked this information with genome wide association studies repositories (see Bioinformatics Tools below).

#### *Randomised clinical trials*

The trial arm containing Hcy-lowering treatment was assigned as the experimental group and compared against placebo, usual care, vitamin-B6 and/or low-dose folic acid. For the stroke outcome, we estimated log relative risk and log upper and log lower 95%CI and pooled estimates across studies using random (DerSimonian & Laird) and fixed (Mantel and Haenszel) effects modelling. The mean difference in change of Hcy between randomised groups ( $\Delta$ -experimental arm minus  $\Delta$ -comparator) was calculated. In a similar fashion to the genetic studies, we evaluated the potential effect of folate status intake on the results of the randomised trials. We conducted meta-regression analysis of the log of the relative risk of the trials against: (i) the probable folate status categories (using the same criteria as for genetic studies) and separately (ii) the mean difference in Hcy achieved by the intervention. Sensitivity analyses were conducted according to: (i) sample size (using 1000 randomised participants as a cut-point to dichotomise studies); (ii) risk of bias (low vs. any/high, according to Cochrane guidance<sup>5</sup>; see **eTable 5**); (iii) the outcome recorded (stroke only vs. stroke plus transient ischaemic attack - we re-estimated the relative risk of stroke for stroke plus TIA in studies where TIA was reported separately as a clinical event (HOPE-2<sup>18</sup>, Righetti<sup>19</sup> and Wrona<sup>6</sup> and; (iv) according to the reference arm used (placebo only vs. [placebo or vitamin-B6 alone]). In addition, the meta-analysis estimate computed by omitting one study at a time was conducted to check that no individual trial had a major influence on the summary estimate (**eFigure 7**). We used the DerSimonian and Laird Q test in all meta-analyses to evaluate the degree of heterogeneity between studies, and the  $I^2$  measure<sup>20</sup> to describe the proportion of total variation in study estimates due to heterogeneity. Funnel plot and Egger regression tests were conducted to evaluate the presence of small-study bias.

#### *Bioinformatics tools*

We used GLIDERS<sup>17</sup> (<http://mather.well.ox.ac.uk/GLIDERS>) to check for potential confounding by long-range linkage disequilibrium (LD). GLIDERS is a web-based tool that allows users to check long-range LD ( $>200$ kb) between SNPs. Using HapMap phase 3, the following criteria were used: Build 36,

MAF $\geq$ 0.05, cis- and trans-chromosome,  $r^2\geq$ 0.3, no lower/upper range (i.e. associations between any pair-wise HapMap SNPs over any distance would be retrieved), and searching all ancestries (Asian, European, African) separately. We searched for SNPs in long-range LD with rs1801133 retrieved from GLIDERS using 2 genome wide association studies repositories for associations with CVD traits and/or outcomes: (1) NHGRI GWAS Catalog<sup>21</sup> and (2) SNPnexus <http://www.snp-nexus.org>. Both were accessed on 30th April 2009.


## References to Supplementary Materials

1. Armitage JM, On behalf of the SEARCH Study Collaborative Group. Late-Breaking Clinical Trial Abstracts From the American Heart Association's Scientific Sessions 2008. Abstract S165: SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine): Randomized Comparison of Folic Acid 2 mg Plus Vitamin B12 1 mg Daily versus Placebo for 7 Years in 12,064 Myocardial Infarction Survivors. *Circulation*. 2008;118(22):2310.
2. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. *Lancet*. 2007 Jun 2;369(9576):1876-82.
3. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. *JAMA*. 2006 Dec 13;296(22):2720-6.
4. Mark SD, Wang W, Fraumeni JF, Jr., Li JY, Taylor PR, Wang GQ, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. *Am J Epidemiol*. 1996 Apr 1;143(7):658-64.
5. Higgins J, Green S, (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.0.2 (updated Sept 2009). The Cochrane Collaboration 2009; Available from: [www.cochrane-handbook.org](http://www.cochrane-handbook.org).
6. Wrono EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrol*. 2004 Feb;15(2):420-6.
7. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA*. 2004 Feb 4;291(5):565-75.
8. Ebbing M, Bleie O, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: a randomized controlled trial. *JAMA*. 2008 Aug 20;300(7):795-804.
9. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med*. 2006 Apr 13;354(15):1578-88.
10. Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. metan: fixed- and random-effects meta-analysis. *Stata Journal*. 2008;8(1):3-28.
11. Little J, Higgins J, (editors). *HuGE Review Handbook* (2004) <http://www.hugenet.org.uk/resources/handbook.php> Accessed 11th April 2010.
12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997 Sep 13;315(7109):629-34.
13. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000 Jun;56(2):455-63.
14. Steichen TJ. Update of tests for publication bias in meta-analysis. *Stata Technical Bulletin Reprints*. 2001;10; STB-57, sbe19.2 p4.
15. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. *Int J Epidemiol*. 2008 Feb;37(1):120-32.
16. Newton-Cheh C, Johnson T, Gateva V, Tobin MD, Bochud M, Coin L, et al. Genome-wide association study identifies eight loci associated with blood pressure. *Nat Genet*. 2009 May 10.
17. Lawrence R, Day-Williams AG, Mott R, Broxholme J, Cardon LR, Zeggini E. GLIDERS--a web-based search engine for genome-wide linkage disequilibrium between HapMap SNPs. *BMC Bioinformatics*. 2009;10:367.
18. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*. 2006 Apr 13;354(15):1567-77.


19. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. *Blood Purif.* 2006;24(4):379-86.
20. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ.* 2003 Sep 6;327(7414):557-60.
21. Hindorff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA. A Catalog of Published Genome-Wide Association Studies. Available at: <http://www.genome.gov/gwastudies> Accessed on 30th April 2009.



**eFigure 1.** Frequency histogram of sample size and number of stroke cases for *MTHFR*-homocysteine (left panel) and *MTHFR*-stroke (right panel) datasets.




**eFigure 2(a) and (b)** Genotype frequency of *MTHFR*/C677T variant in studies used to determine the effect on homocysteine levels, classified by (a) ethnicity, and (b) probable folate status categories.



**Footnote**

Only studies with data on all 3 genotypes are presented


eFigure 2(b)



**Footnote**


Only studies with data on all 3 genotypes are presented

**eFigure 3(a) and (b)** Genotype frequency of *MTHFR*/C677T variant in studies utilised to estimate the effect on stroke, according to frequency in control samples, classified by (a) ethnicity, and (b) probable folate status category.




**Footnote**  
Only studies with data on all 3 genotypes are presented

**eFigure 3(b)**




**Footnote**  
Only studies with data on all 3 genotypes are presented


**eFigure 4** Odds ratio of the *MTHFR*/C677T variant on different stroke sub-types. Left panel compares individuals homozygous for T allele with CC subjects. Right panel compares heterozygous with CC subjects.



**eFigure 5** Contour-enhanced funnel plot of *MTHFR*-stroke studies in Asia using the trim and fill analysis. The black dots represent the observed studies and the grey triangles represent hypothetical missing studies.




**eFigure 6.** Odds ratio of the *MTHFR*/C677T variant on stroke stratified according to the tertile of difference in homocysteine determined by the genetic variant. Left panel compares individuals homozygous for T-allele with CC subjects. Right panel compares heterozygous with CC subjects.





**eFigure 7** Influence analysis to evaluate the effect of individual trials, omitted one at a time, on the summary estimate of randomised clinical trials of homocysteine-lowering interventions in stroke risk.



## Supplementary Tables

**eTable 1.** Characteristics of genetic studies included in the analysis of *MTHFR/C677T* and homocysteine levels.

**eTable 2.** Characteristics of genetic studies included in the analysis of *MTHFR/C677T* and stroke risk.

**eTable 3.** Sensitivity analysis to illustrate the number of hypothetical large null studies that are needed to shift the point estimate observed in the *MTHFR/C677T*-stroke meta-analysis to several thresholds.

**eTable 4.** Linkage disequilibrium of the *MTHFR/C677T* variant by ethnic group.

**eTable 5.** Characteristics of randomised clinical trials of homocysteine-lowering interventions in stroke.

**Table 1.** Characteristics of genetic studies included in the analysis of *MTHFR/C677T* and homocysteine levels.

Study	Reference	Years conducted	Proxy year of study conduct †	Country where study performed	Folate regional supplementation	Ethnicity	Male (%)	Mean age (years)	No TT-genotype (all)	No CT-genotype (all)	No CC-genotype (all)	TT expected	CT expected	CC expected	HWE (p-value)	Disequilibrium coefficient
Nakata Y	s057a	1992-1995	NA	Japan	Asia	East Asian	NR	NR	30	92	66	30.72	90.55	66.72	0.8800	-0.0038
Yoo JH-2000	s029a	1996-1997	NA	Korea	Asia	East Asian	53	52	16	64	42	18.89	58.23	44.89	0.3440	-0.0236
Kohara K	s062a	1997-1999	NA	Japan	Asia	East Asian	50	NR	305	956	744	305.78	954.44	744.78	0.9626	-0.0004
Li Z	s058a	2000-2001	NA	China	Asia	East Asian	57	NR	398	824	610	358.13	903.73	570.13	0.0002	0.0218
Choi BO	s059a	2000-2002	NA	Korea	Asia	East Asian	56	NR	25	100	73	28.41	93.18	76.41	0.3654	-0.0172
Kim OJ2	s068b	2000-2002	NA	Korea	Asia	East Asian	53	NR	38	119	66	42.63	109.74	70.63	0.2243	-0.0208
Kim NK	s061a	2000-2003	NA	South Korea	Asia	East Asian	45	NR	16	71	39	21.05	60.90	44.05	0.0960	-0.0401
Biswas A	s075a	2003-2004	NA	India	Asia	South Asian	NR	NR	4	26	46	3.80	26.39	45.80	1.0000	0.0026
Ou T	s035	NR	1996	Japan	Asia	East Asian	86	55	27	19	39	15.67	41.65	27.67	0.0000	0.1333
Ho CH	s008	NR	1998	China	Asia	East Asian	68	64	69	164	212	51.24	199.52	194.24	0.0002	0.0399
Vizcaino G	s036	NR	1999	India	Asia	South Asian	NR	30	14	50	27	16.71	44.57	29.71	0.2907	-0.0298
Somekawa Y	s012	NR	2000	Japan	Asia	East Asian	0	55	30	91	96	26.27	98.46	92.27	0.2945	0.0172
Jee SH	s032a	NR	2000	Korea	Asia	East Asian	44	37	76	184	135	71.45	193.09	130.45	0.3550	0.0115
Yingdong Z	s040a	NR	2000	China	Asia	East Asian	48	59	5	16	21	4.02	17.95	20.02	0.4809	0.0232
Huang Y	s060b	NR	2000	China	Asia	East Asian	NR	NR	11	26	18	10.47	27.05	17.47	0.7870	0.0096
Miyaki K	s069a	NR	2002	Japan	Asia	East Asian	77	NR	10	24	17	9.49	25.02	16.49	0.7791	0.0100
Fang X	s064a	NR	2003	Mongolia	Asia	East Asian	54	NR	2	6	16	1.04	7.92	15.04	0.2324	0.0399
Kim IG	s074a	NR	2005	Korea	Asia	East Asian	45	NR	15	61	34	18.82	53.36	37.82	0.1705	-0.0347
Voutilainen S	s010	1984-1996	NA	Finland	Europe-low	Caucasian	100	54	11	57	100	9.29	60.43	98.29	0.5185	0.0102
Thogersen AM	s002a	1986-1994	NA	Sweden	Europe-low	Caucasian	79	55	7	51	71	8.19	48.62	72.19	0.8147	-0.0092
Meleady R	s027a	1990-1992	NA	9 European Countries	Europe-low	Caucasian	72	44	81	314	352	75.83	324.34	346.83	0.3994	0.0069
Slooter AJ	s071a	1990-2001	NA	Netherlands	Europe-low	Caucasian	0	NR	59	274	292	61.47	269.07	294.47	0.7102	-0.0039
Frederiksen J	s066b	1991-2002	NA	Denmark	Europe-low	Caucasian	42	NR	315	1600	1804	334.29	1561.42	1823.29	0.1378	-0.0052
de Bree A.	s034	1993-1996	NA	Netherlands	Europe-low	Caucasian	53	41	206	907	983	207.51	903.98	984.51	0.9193	-0.0007
Cappuccio FP	s018	1994-1996	NA	UK	Europe-low	Mixed ethnicity	45	50	64	391	916	49.12	420.76	901.12	0.0105	0.0109
Husemoen LLN	s023	1999-2001	NA	Finland	Europe-low	Caucasian	48	46	246	1181	1361	250.98	1171.04	1365.98	0.6849	-0.0018
Hustad S	s028	NR	1998	Norway	Europe-low	Caucasian	62	41	37	182	204	38.73	178.53	205.73	0.7308	-0.0041
Silaste ML	s014	NR	1999	Finland	Europe-low	Caucasian	0	NR	5	13	19	3.57	15.85	17.57	0.2679	0.0385
Shmeleva V	s073a	NR	2003	Russia	Europe-low	Caucasian	NR	NR	6	30	24	7.35	27.30	25.35	0.5746	-0.0225
Karakus Z	s076a	NR	2003	Turkey	Europe-low	Caucasian	52	NR	7	36	37	7.81	34.38	37.81	0.7977	-0.0102
Dikmen M	s063b	NR	2004	Turkey	Europe-low	Caucasian	29	NR	2	21	32	2.84	19.32	32.84	0.7110	-0.0153
D'Angelo A.	s037a	1996	NA	Italy	Europe-mid	Caucasian	52	41	39	98	45	42.55	90.90	48.55	0.3727	-0.0195
Dekou V.	s009a	1996	NA	England	Europe-mid	Caucasian	0	66	36	149	161	35.29	150.42	160.29	0.9016	0.0021
Dekou V.	s009b	1996	NA	England	Europe-mid	Caucasian	100	66	36	188	184	41.42	177.16	189.42	0.2543	-0.0133
Chango A	s017	1997	NA	France	Europe-mid	Caucasian	45	NR	49	125	117	42.72	137.55	110.72	0.1362	0.0216
Reyes-Engel A	s024	1998	NA	Spain	Europe-mid	Caucasian	49	45	119	413	249	135.66	379.68	265.66	0.0153	-0.0213
NPHS_II	s072b	1989-2005	NA	United Kingdom	Europe-mid	Caucasian	100	NR	150	579	631	142.03	594.94	623.03	0.3217	0.0059
Fowkes G	s065b	1992-2002	NA	United Kingdom	Europe-mid	Caucasian	NR	NR	60	323	315	70.29	302.42	325.29	0.0807	-0.0147
Meisel C	s007a	1995-1997	NA	Germany	Europe-mid	Caucasian	76	61	96	217	120	96.58	215.83	120.58	1.0000	-0.0013
Chambers JC	s004c	1995-1998	NA	UK	Europe-mid	Caucasian	100	50	41	195	188	45.24	186.52	192.24	0.3787	-0.0100
Chambers JC	s004a	1995-1998	NA	UK	Europe-mid	South Asian	100	49	12	90	279	8.53	96.94	275.53	0.1596	0.0091
Gemmati D	s039a	1996-1997	NA	Italy	Europe-mid	Caucasian	61	47	39	116	65	42.77	108.46	68.77	0.3402	-0.0171
Pezzini A	s070b	1997-2000	NA	Italy	Europe-mid	Caucasian	54	NR	20	60	50	19.23	61.54	49.23	0.8529	0.0059
Domagala TB	s016a	1998-2000	NA	Poland	Europe-mid	Caucasian	72	45	6	37	57	6.00	36.99	57.00	1.0000	0.0000
HAPIEE study	S176	2002-2005	NA	Czech Republic, Poland, Russ	Europe-mid	Caucasian	47	NR	70	273	312	65.10	282.79	307.10	0.3667	0.0075
Thuillier L	s011a	NR	1996	France	Europe-mid	Caucasian	34	43	10	32	27	9.80	32.41	26.80	1.0000	0.0029
Zittoun J	s038	NR	1996	France	Europe-mid	Caucasian	46	33	6	20	26	4.92	22.15	24.92	0.5179	0.0207
Friedman G	s022	NR	1997	Israel	Europe-mid	Caucasian	50	57	55	172	150	52.73	176.53	147.73	0.6598	0.0060
Chango A	s020	NR	1998	France	Europe-mid	Caucasian	45	NR	12	25	29	9.09	30.81	26.09	0.1220	0.0440
Passaro A	s030	NR	1999	Italy	Europe-mid	Caucasian	0	62	20	72	28	26.13	59.73	34.13	0.0295	-0.0511
Pullin C	s031	NR	1999	UK	Europe-mid	Caucasian	42	39	42	42	42	31.50	63.00	31.50	0.0002	0.0833
Litynski P	s033	NR	2000	Switzerland	Europe-mid	Caucasian	80	NR	20	NR	20	NA	NA	NA	NA	NA
Fohr IP	s005	NR	2000	Germany	Europe-mid	Caucasian	0	24	21	75	64	21.39	74.22	64.39	1.0000	-0.0024
Castro R	s019	NR	2001	Portugal	Europe-mid	Caucasian	39	41	12	54	51	13.00	52.00	52.00	0.8353	-0.0085
Hassan A	s067b	NR	2002	United Kingdom	Europe-mid	Caucasian	58	NR	49	144	147	43.06	155.88	141.06	0.1573	0.0175
Linnebank M	s078	NR	2004	Germany	Europe-mid	Caucasian	NR	NR	8	67	64	12.39	58.22	68.39	0.1045	-0.0316
Ma J	s021a	1982	NA	USA	America-ANZ mid	Caucasian	100	60	39	116	193	27.04	139.93	181.04	0.0020	0.0344
Christensen B.	s026a	1986-1987	NA	Canada	America-ANZ mid	Caucasian	100	42	8	47	31	11.54	39.92	34.54	0.1615	-0.0411
Jacques PF	s013	1991-1994	NA	USA	America-ANZ mid	Caucasian	50	57	149	152	149	112.50	225.00	112.50	0.0000	0.0811
Schwartz SM	s025	1991-1995	NA	USA	America-ANZ mid	Caucasian	0	NR	43	141	154	38.11	150.77	149.11	0.2251	0.0145
Varela MI	s041a	1997-2000	NA	Argentina	America-ANZ mid	Latin American	56	40	22	73	49	23.77	69.47	50.77	0.6068	-0.0123
Schmitz C	s003	1996	NA	USA	America-ANZ high	Caucasian	NR	59	56	156	166	47.50	172.99	157.50	0.0566	0.0225
Guinotte ChL	s006	1998	NA	USA	America-ANZ high	Caucasian	100	25	17	12	14	12.30	21.40	9.30	0.0052	0.1092
Caudill MA	s001	1999	NA	USA	America-ANZ high	Caucasian	0	26	9	50	75	8.63	50.73	74.63	0.8221	0.0028

Zee RY_WHS	s077b	1992-2000	NA	USA	America-ANZ high	Caucasian	0	NR	2773	10966	11229	2729.96	11052.09	11185.96	0.2189	0.0017
Eikelboom JW	s056a	1996-1998	NA	Australia	America-ANZ high	Caucasian	60	NR	23	98	84	25.29	93.42	86.29	0.5419	-0.0112
Bailey LB	s015	NR	2000	USA	America-ANZ high	Caucasian	0	NR	23	62	100	15.76	76.48	92.76	0.0123	0.0391

**Footnotes**

Arranged by folate regional supplementation.

† year of conduct calculated for unknown studies by subtracting the median time between study conclusion and publication date (2 years)

For HWE calculations, allele frequencies from all individuals included

References with suffix a,b,c denotes different datasets used from same study

ANZ: Australia & New Zealand; NR: Not reported; NA: Not applicable



Rotterdam Study	s174b	Haemorrhagic	1990+	NA	Netherlands	Europe-low	Caucasian	NR	631	2774	2807	655.56	2724.88	2831.56	0.1650	-0.0040	
De Stefano V	s101	Ischaemic	1994-1997	NA	Italy	Europe-mid	Caucasian	NR	39	35	98	65	35.64	96.73	65.64	0.8854	-0.0032
Reuner KH	s093	Ischaemic	NR	1996	Germany	Europe-mid	Caucasian	NR	23	74	85	19.78	80.44	81.78	0.3137	0.0177	
Salooja N	s097	Ischaemic	NR	1996	United Kingdom	Europe-mid	Caucasian	NR	53	16	76	81	16.86	74.29	81.86	0.8602	-0.0049
Lalouschek W	s100	Ischaemic	NR	1997	Austria	Europe-mid	Caucasian	NR	60	10	47	39	11.69	43.62	40.69	0.5084	-0.0176
Margaglione M	s105	Ischaemic	1996-1998	NA	Italy	Europe-mid	Caucasian	NR	43	196	513	327	197.64	509.72	328.64	0.8500	-0.0016
Harmon DL	s107	Ischaemic	1996-1997	NA	Ireland	Europe-mid	Caucasian	NR	25	19	78	86	18.38	79.23	85.38	0.8646	0.0034
Gross B	s116	Ischaemic	NR	1998	Israel	Europe-mid	Caucasian	NR	15	50	47	14.29	51.43	46.29	0.8369	0.0064	
Topic E	s112	Ischaemic	NR	1999	Croatia	Europe-mid	Caucasian	NR	1	59	64	7.50	46.00	70.50	0.0012	-0.0524	
De Stefano V	s117	Ischaemic	NR	1999	Italy	Europe-mid	Caucasian	NR	53	80	197	205	66.10	224.79	191.10	0.0082	0.0288
Lopaciuk S	s099	Ischaemic	1996-1999	NA	Poland	Europe-mid	Caucasian	NR	66	26	95	117	22.70	101.60	113.70	0.3614	0.0139
Pezzini A	s109	Ischaemic	1997-2000	NA	Italy	Europe-mid	Caucasian	NR	64	4	14	18	3.36	15.28	17.36	0.6952	0.0177
Pongracz E	s113c	Ischaemic	NR	2000	Hungary	Europe-mid	Caucasian	NR	7	46	120	5.20	49.60	118.20	0.2998	0.0104	
Mclroy SP	s162	Ischaemic	NR	2000	Ireland	Europe-mid	Caucasian	NR	20	2	19	50	1.86	19.27	49.86	1.0000	0.0019
Grossmann R	s092	Ischaemic	1997-2000	NA	Germany	Europe-mid	Caucasian	NR	49	26	91	69	27.49	88.03	70.49	0.7567	-0.0080
Szolnoki Z	s102	Ischaemic	1998-2002	NA	Hungary	Europe-mid	Caucasian	NR	53	89	268	386	66.93	312.14	363.93	0.0002	0.0297
Pezzini A	s106	Ischaemic	1997-2000	NA	Italy	Europe-mid	Caucasian	NR	54	23	72	54	23.36	71.28	54.36	1.0000	-0.0024
Pratnicka M	s118d	Ischaemic	NR	2001	Poland	Europe-mid	Caucasian	NR	8	54	88	8.17	53.67	88.17	1.0000	-0.0011	
Hassan A	s067a	Ischaemic	NR	2002	United Kingdom	Europe-mid	Caucasian	NR	58	16	73	81	16.21	72.57	81.21	1.0000	-0.0013
Linnebank M	s137	Ischaemic	1999-2001	NA	Germany	Europe-mid	Caucasian	NR	50	19	62	78	15.72	68.55	74.72	0.2685	0.0206
Pezzini A	s138	Ischaemic	1997-2002	NA	Italy	Europe-mid	Caucasian	NR	54	23	75	60	23.17	74.67	60.17	1.0000	-0.0005
Szolnoki Z	s143	Ischaemic	1998-2003	NA	Hungary	Europe-mid	Caucasian	NR	53	23	106	166	19.58	112.84	162.58	0.2892	0.0116
ye H	s079	Ischaemic	1999-2003	NA	Italy	Europe-mid	Caucasian	NR	67	97	286	232	93.66	292.68	228.66	0.6111	0.0054
Bosco P	s128	Ischaemic	NR	2004	Italy	Europe-mid	Caucasian	NR	60	19	67	35	22.78	59.44	38.78	0.1977	-0.0312
Sazci A	s142c	Ischaemic	2001-2003	NA	Turkey	Europe-mid	Caucasian	NR	56	25	119	115	27.57	113.86	117.57	0.5715	-0.0099
Szolnoki Z	s144	Ischaemic	1998-2003	NA	Hungary	Europe-mid	Caucasian	NR	10	32	60	6.63	38.75	56.63	0.1135	0.0331	
Sanchez Marin J	s171c	Ischaemic	1998-2001	NA	Spain	Europe-mid	Caucasian	NR	57	14	43	33	14.00	42.99	33.00	1.0000	0.0000
Pezzini A	s070a	Ischaemic	1997-2000	NA	Italy	Europe-mid	Caucasian	NR	54	22	73	60	22.08	72.84	60.08	1.0000	-0.0005
Lalouschek W	s136	Ischaemic	1998-2001	NA	Austria	Europe-mid	Caucasian	NR	52	90	366	361	91.22	363.55	362.22	0.8753	-0.0015
Pezzini A	s139	Ischaemic	1997-2000	NA	Italy	Europe-mid	Caucasian	NR	0	22	110	84	27.45	99.10	89.45	0.1377	-0.0252
NPHS_II	s072d	Ischaemic	1989-2003	NA	United Kingdom	Europe-mid	Caucasian	NR	100	251	1128	1241	253.52	1122.96	1243.52	0.8553	-0.0010
Salooja N	s097a	Total stroke (isch+haem)	NR	1996	United Kingdom	Europe-mid	Caucasian	NR	53	16	76	81	16.86	74.29	81.86	0.8602	-0.0049
Fowkes G	s065a	Total stroke (isch+haem)	1992-2002	NA	United Kingdom	Europe-mid	Caucasian	NR	48	73	398	405	84.46	375.09	416.46	0.0824	-0.0131
Pongracz E	s113a	Total stroke (isch+haem)	NR	2000	Hungary	Europe-mid	Caucasian	NR	7	46	120	5.20	49.60	118.20	0.2998	0.0104	
Hermans MP	s129	Total stroke (isch+haem)	NR	2003	Belgium	Europe-mid	Caucasian	NR	58	22	58	62	18.32	65.37	58.32	0.2015	0.0259
Gutierrez JI	s134	Total stroke (isch+haem)	NR	2003	Spain	Europe-mid	Caucasian	NR	49	24	79	56	25.36	76.28	57.36	0.7417	-0.0086
Sazci A	s142a	Total stroke (isch+haem)	2001-2003	NA	Turkey	Europe-mid	Caucasian	NR	56	25	119	115	27.57	113.86	117.57	0.5715	-0.0099
Sanchez Marin J	s171a	Total stroke (isch+haem)	1998-2001	NA	Spain	Europe-mid	Caucasian	NR	57	14	43	33	14.00	42.99	33.00	1.0000	0.0000
British Women Heart & Health	s130	Total stroke (isch+haem)	1999-2007	NA	United Kingdom	Europe-mid	Caucasian	NR	0	400	1515	1553	386.33	1542.33	1539.33	0.3026	0.0039
NPHS II	s072a	Total stroke (isch+haem)	1989-2003	NA	United Kingdom	Europe-mid	Caucasian	NR	100	251	1128	1241	253.52	1122.96	1243.52	0.8553	-0.0010
EPIC Norfolk	s175	Total stroke (isch+haem)	1997+	NA	United Kingdom	Europe-mid	Caucasian	NR	1982	7964	7956	1986.89	7954.22	7960.89	0.8797	-0.0003	
Weikert C	s177	Total stroke (isch+haem)	1994-2004	NA	Germany	Europe-mid	Caucasian	NR	45	92	421	455	94.53	415.94	457.53	0.7648	-0.0026
Salooja N	s097b	Haemorrhagic	NR	1996	United Kingdom	Europe-mid	Caucasian	NR	53	16	76	81	16.86	74.29	81.86	0.8602	-0.0049
Pongracz E	s113b	Haemorrhagic	NR	2000	Hungary	Europe-mid	Caucasian	NR	7	46	120	5.20	49.60	118.20	0.2998	0.0104	
Sanchez Marin J	s142b	Haemorrhagic	1998-2001	NA	Spain	Europe-mid	Caucasian	NR	57	14	43	33	14.00	42.99	33.00	1.0000	0.0000
Sazci A	s171b	Haemorrhagic	2001-2003	NA	Turkey	Europe-mid	Caucasian	NR	56	25	119	115	27.57	113.86	117.57	0.5715	-0.0099
NPHS II	s072c	Haemorrhagic	1989-2003	NA	United Kingdom	Europe-mid	Caucasian	NR	100	251	1128	1241	253.52	1122.96	1243.52	0.8553	-0.0010
Linnebank M	s169	Haemorrhagic	1999-2001	NA	Germany	Europe-mid	Caucasian	NR	36	152	158	36.25	151.49	158.25	1.0000	-0.0007	
Voetsch B	s104a	Ischaemic	1996-1998	NA	Brazil	America-ANZ mid	Latin American	NR	44	2	43	61	5.21	36.58	64.21	0.0936	-0.0303
Voetsch B	s104b	Ischaemic	1996-1998	NA	Brazil	America-ANZ mid	Latin American	NR	44	14	57	48	15.18	54.64	49.18	0.6944	-0.0099
Voetsch B	s146	Ischaemic	1996-2000	NA	Brazil	America-ANZ mid	Mixed	NR	46	11	66	41	16.41	55.19	46.41	0.0484	-0.0458
Shinjo SK	s172	Ischaemic	1994-2004	NA	Brazil	America-ANZ mid	Latin American	NR	57	12	60	54	14.00	56.00	56.00	0.5476	-0.0159
Press RD	s111	Ischaemic	NR	1997	USA	America-ANZ high	Caucasian	NR	58	1	23	28	3.00	18.99	30.00	0.2505	-0.0386
Eikelboom JW	s056d	Ischaemic	1996-1998	NA	Australia	America-ANZ high	Caucasian	NR	60	23	98	84	25.29	93.42	86.29	0.5419	-0.0112
Zee RL	s077a	Ischaemic	1992-2000	NA	USA	America-ANZ high	Caucasian	NR	0	2773	10966	11229	2729.96	11052.09	11185.96	0.2189	0.0017
Eikelboom JW	s056b	Total stroke (isch+haem)	1996-1998	NA	Australia	America-ANZ high	Caucasian	NR	60	23	98	84	25.29	93.42	86.29	0.5419	-0.0112
Eikelboom JW	s056c	Haemorrhagic	1996-1998	NA	Australia	America-ANZ high	Caucasian	NR	60	23	98	84	25.29	93.42	86.29	0.5419	-0.0112
ISGS-SWISS	s179	Ischaemic	200-2009	NA	USA	America-ANZ high	Caucasian	NR	48	186	670	632	182.42	677.16	628.42	0.6902	0.0024

**Footnotes**

† Arranged by folate regional supplementation.

‡ year of conduct calculated for unknown studies by subtracting the median time between study conclusion and publication date (2 years)

§ we used the measure of effect for the genotype comparisons reported in the manuscript

¶ For HWE calculations, allele frequencies from controls were used only in case control studies; in cohort studies we used values for the entire study population.

References with suffix a,b,c denotes different datasets used from same study. Studies that reported separate stroke subtypes appear more than once.

ANZ: Australia & New Zealand; NR: Not reported; NA: Not applicable

**Table 3.** Sensitivity analysis to illustrate the number of hypothetical large null studies that are needed to shift the point estimate observed in the *MTHFR* /C677T-stroke meta-analysis to several thresholds.

Analysis	<i>MTHFR</i> TT vs. CC – Asia (low folate region)			
	All studies		Large-studies (≥400 cases)	
	No. of hypothetical studies	OR (95%CI)	No. of hypothetical studies	OR (95%CI)
<b>Observed result meta-analysis</b>	0	1.68 (1.44, 1.97)	0	1.28 (1.11, 1.48)
<b>Reduce point estimate to 1.15</b>	41	1.15 (1.07, 1.23)	6	1.14 (1.03, 1.27)
<b>Reduce point estimate to 1.10</b>	60	1.10 (1.04, 1.16)	12	1.10 (1.00, 1.20)
<b>Lower 95%CI to cross line of 1.00</b>	260	1.02 (1.00, 1.05)	14	1.09 (1.00, 1.18)

**Footnotes**

The sample size of the hypothetical studies was 400 cases and 400 controls with equal distribution to TT and CC alleles – i.e. generating an OR of 1.0 (95%CI: 0.76, 1.32).

Each hypothetical study was added to the dataset of studies on *MTHFR* -stroke using cumulative meta-analysis techniques.

**eTable 4.** Linkage disequilibrium of the *MTHFR* /C677T variant by ethnic group.

Ancestry	SNP rs number	Chromosome number	Position (base pair)	r2 with rs1801133	Complex disease association	
					SNPnexus†	GWAS catalog‡
Asian	9651118	1	11784801	0.38	none	none
	7554327	1	11784801	0.31	none	none
	2336377	1	11872557	0.3	none	none
	2639453	1	11905131	0.33	none	none
European	6540999	1	11755953	0.32	none	none
	11121828	1	11757041	0.32	none	none
	7538516	1	11759269	0.32	none	none
	6697244	1	11761435	0.32	none	none
	4845882	1	11765754	0.34	none	none
	1994798	1	11777342	0.35	none	none
	6541003	1	11778454	0.36	none	none
	4846052	1	11780538	0.37	none	none
	4846054	1	11791817	0.34	none	none
	12404124	1	11796456	0.37	none	none
	198391	1	11799004	0.37	none	none
	198393	1	11802272	0.37	none	none
	198401	1	11810971	0.38	none	none
	535107	1	11812055	0.37	none	none
198406	1	11820179	0.37	none	none	
Africa	4846052	1	11780538	0.56	none	none
	198401	1	11810971	0.62	none	none
	2639453	1	11905131	0.35	none	none

**Footnotes**

SNPs in long-range LD with rs1801133 identified through Genome-wide Linkage Disequilibrium Repository and Search (GLIDERS) from HapMap phase 3 Build 36, MAF $\geq$ 0.05, cis- and trans-chromosome, r $\geq$ 0.3, no lower/upper range - i.e. associations between any pair-wise HapMap SNPs over any distance would be retrieved (<http://mather.well.ox.ac.uk/GLIDERS>). Accessed 30th April 2010

† SNPnexus (<http://www.snp-nexus.org>); all SNPs uploaded using population data from HapMap (not limited to any ancestry) and outcome listed for Complex Diseases and Disorders. Accessed 30th April 2010

‡ from Hindorff LA, Junkins HA, Mehta JP, and Manolio TA. A Catalog of Published Genome-Wide Association Studies. Available at: [www.genome.gov/gwastudies](http://www.genome.gov/gwastudies). Accessed 30th April 2010.

SNP-trait associated traits are limited to those with P $<$ 1.0 x 10<sup>-5</sup>; studies reported in the catalog have genotyped at least 100,000 SNPs in the initial stage.



eTable 5. Characteristics of randomised clinical trials of homocysteine-lowering interventions in stroke

Trial (reference)	Years conducted	Characteristics of participants at study entry	Outcome reported	Geographical Location	Folic acid			Comparator arm (B vitamins and/or placebo or usual care)			Follow-up (months)	Mean Age (years)	Participants with homocysteine measured (%)	Folic acid dose (mg/day)	Vit-B12 dose (mg/day)	Vit-B6 dose (mg/day)	Reference arm	Risk of Bias evaluation (using Cochrane collaboration nomenclature)				
					Number randomised	Stroke only (fatal and non-fatal)	TIA only	Number randomised	Stroke only (fatal and non-fatal)	TIA only								Sequence generation	Allocation concealment	Blinding	Incomplete outcome data	Selective outcome reporting
Righetti (45)	2001-2005	Chronic kidney disease	Fatal and nonfatal stroke and TIA	Italy	37	1	3	51	2	8	29	64	†	5	0.25	125	Placebo	low-risk	low-risk	unclear	low-risk	low-risk
House (49)	2001-2007	Type 1 or 2 diabetes and diabetic nephropathy	Stroke (fatal and non-fatal) ‡	Canada	128	6	NA	124	1	NA	32	60.4		2.5	1	25	Placebo	low-risk	low-risk	low-risk	low-risk	low-risk
Liem (42)	1998-2002	Stable CHD	Fatal stroke, non-fatal stroke and TIA	Netherlands	300	8*	NA	293	12*	NA	42	65	‡	0.5	0	0	Usual care	low-risk	unclear	high-risk	low-risk	low-risk
Zoungas (50)	1998-2003	Chronic kidney disease	Fatal and nonfatal stroke	Australia, New Zealand	156	8	NA	159	18	NA	43	56	†	15	0	0	Placebo	unclear	unclear	low-risk	low-risk	low-risk
Wrone (51)	1998-2000	Chronic kidney disease	Stroke (unspecified) and TIA	USA	351.8	19	6	177	8	1	24	60	†	5 or 15	0.006	12.5	1 mg/d folic acid	low-risk	low-risk	low-risk	low-risk	low-risk
Jamison (52)	2001-2003	Chronic kidney disease	Fatal and nonfatal thromboembolic stroke	USA	1032	37	NA	1024	41	NA	38	66	113 (5.5)	40	2	100	Placebo	low-risk	unclear	low-risk	low-risk	low-risk
Ebbing (43)	1999-2006	Stable angina, ACS or aortic valve stenosis	Nonfatal thromboembolic stroke and fatal stroke	Norway	1544	28	NA	1552	39	NA	38	61	2557 (82.6)	0.8	0.4	40	Placebo / B6	low-risk	low-risk	low-risk	low-risk	high-risk
Bonaa (44)	1998-2002	Myocardial infarction	Any fatal and nonfatal stroke (including SAH)	Norway	1872	49	NA	1877	49	NA	36	63	3027 (80.7)	0.8	0.4	40	Placebo / B6	low-risk	low-risk	low-risk	low-risk	low-risk
Albert (53)	1998-2005	CVD or 3 risk factors for CVD	Fatal and nonfatal stroke (ischaemic, haemorrhagic)	USA	2721	79	NA	2721	69	NA	87	64	600 (11)	2.5	1	50	Placebo	unclear	unclear	low-risk	low-risk	low-risk
HOPE-2 (48)	2000-2005	CVD or diabetes	Fatal and nonfatal stroke (ischaemic, haemorrhagic) and TIA	Canada, USA (72.1 %); Brazil, Western Europe, Slovakia (27.9 %)	2758	111	131	2764	147	120	60	69	1064 (19.3)	2.5	1	50	Placebo	low-risk	low-risk	low-risk	low-risk	low-risk
Toole (54)	1996-2003	Ischaemic Stroke	Recurrent ischaemic stroke (fatal & non-fatal)	USA, Canada, Scotland	1827	152	NA	1853	148	NA	24	66	†	2.5	0.4	25	20 micro g/d folic acid †	low-risk	low-risk	low-risk	low-risk	low-risk
SEARCH (46)	1998-2005	Myocardial infarction	Any fatal and nonfatal stroke (including SAH)	United Kingdom	6033	269	NA	6031	265	NA	80	64	§ (10)	2	1	0	Placebo	low-risk	low-risk	low-risk	low-risk	low-risk
VITATOPS (47)	1998-2009	Stroke or TIA	Fatal and nonfatal stroke	20 Countries †	4089	360	NA	4075	388	NA	41	62.6	1164 (14.3)	2	0.5	25	Placebo	low-risk	low-risk	low-risk	low-risk	low-risk

**Footnotes**

Studies were independently reviewed for risk of bias (MVH and JPC)  
 ACS, acute coronary syndrome; CHD, coronary heart disease; CVD, cardiovascular disease; SAH, subarachnoid haemorrhage; TIA, transient ischaemic attack  
 \* TIA reported together with stroke values  
 † No specific value reported in manuscript for the number of participants tested for Hcy  
 ‡ Only the group randomised to intervention was tested for Hcy at follow-up  
 § No absolute value of the number of participants tested for Hcy recorded in manuscript (percentage reported)  
 † reference arm also contained 200 µg B6 and 5µg of B12  
 ‡ For Wrone (51), we combined doses of 15mg/day and 5mg/day folic acid together as the intervention arm against the comparator group of 1mg/day folic acid  
 § House (49) used the same diagnostic criteria as Toole (54)  
 † 20 countries: Australia, Austria, Belgium, Brazil, Hong Kong, India, Italy, Malaysia, Moldova, Netherlands, New Zealand, Pakistan, Philippines, Portugal, Republic of Georgia, Serbia & Monte Negro, Singapore, Sri Lanka, United Kingdom and United States of America

## Supplementary References

- s1. Caudill MA, Le T, Moonie SA, Esfahani ST, Cogger EA. Folate status in women of childbearing age residing in Southern California after folic acid fortification. *J Am Coll Nutr.* 2001;20:129-34
- s2. Thogersen AM, Nilsson TK, Dahlen G, Jansson JH, Boman K, Huhtasaari F, et al. Homozygosity for the C677-->T mutation of 5,10-methylenetetrahydrofolate reductase and total plasma homocysteine are not associated with greater than normal risk of a first myocardial infarction in northern Sweden. *Coron Artery Dis.* 2001;12:85-90.
- s3. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. *Circulation.* 1996;94:1812-4.
- s4. Chambers JC, Ireland H, Thompson E, Reilly P, Obeid OA, Refsum H, et al. Methylenetetrahydrofolate reductase 677 C-->T mutation and coronary heart disease risk in UK Indian Asians. *Arterioscler Thromb Vasc Biol.* 2000;20:2448-52.
- s5. Fohr IP, Prinz-Langenohl R, Bronstrup A, Bohlmann AM, Nau H, Berthold HK, et al. 5,10-Methylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. *Am J Clin Nutr.* 2002;75:275-82.
- s6. Guinotte CL, Burns MG, Axume JA, Hata H, Urrutia TF, Alamilla A, et al. Methylenetetrahydrofolate reductase 677C-->T variant modulates folate status response to controlled folate intakes in young women. *J Nutr.* 2003;133:1272-80.
- s7. Meisel C, Cascorbi I, Gerloff T, Stangl V, Laule M, Muller JM, et al. Identification of six methylenetetrahydrofolate reductase (MTHFR) genotypes resulting from common polymorphisms: impact on plasma homocysteine levels and development of coronary artery disease. *Atherosclerosis.* 2001;154:651-8.
- s8. Ho CH. The influence of age, sex, vitamin B(12), folate levels and methylenetetrahydrofolate reductase C677T genetic mutations on plasma homocysteine in the Chinese population. *Haematologica.* 2000;85:1051-4.
- s9. Dekou V, Whincup P, Papacosta O, Ebrahim S, Lennon L, Ueland PM, et al. The effect of the C677T and A1298C polymorphisms in the methylenetetrahydrofolate reductase gene on homocysteine levels in elderly men and women from the British regional heart study. *Atherosclerosis.* 2001;154:659-66.
- s10. Voutilainen S, Lakka TA, Hamelahti P, Lehtimaki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. *J Intern Med.* 2000;248:217-22.
- s11. Thuillier L, Chadeaux-Vekemans B, Bonnefont JP, Kara A, Aupetit J, Rochette C, et al. Does the polymorphism 677C-T of the 5,10-methylenetetrahydrofolate reductase gene contribute to homocysteine-related vascular disease? *J Inherit Metab Dis.* 1998;21:812-22.
- s12. Somekawa Y, Kobayashi K, Tomura S, Aso T, Hamaguchi H. Effects of hormone replacement therapy and methylenetetrahydrofolate reductase polymorphism on plasma folate and homocysteine levels in postmenopausal Japanese women. *Fertil Steril.* 2002;77:481-6.
- s13. Jacques PF, Kalmbach R, Bagley PJ, Russo GT, Rogers G, Wilson PW, et al. The relationship between riboflavin and plasma total homocysteine in the Framingham Offspring cohort is influenced by folate status and the C677T transition in the methylenetetrahydrofolate reductase gene. *J Nutr.* 2002;132:283-8.
- s14. Silaste ML, Rantala M, Sampi M, Alfthan G, Aro A, Kesaniemi YA. Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. *J Nutr.* 2001;131:2643-7.
- s15. Bailey LB, Duhaney RL, Maneval DR, Kauwell GP, Quinlivan EP, Davis SR, et al. Vitamin B-12 status is inversely associated with plasma homocysteine in young women with C677T and/or A1298C methylenetetrahydrofolate reductase polymorphisms. *J Nutr.* 2002;132:1872-8.

- s16. Domagala TB, Adamek L, Nizankowska E, Sanak M, Szczeklik A. Mutations C677T and A1298C of the 5,10-methylenetetrahydrofolate reductase gene and fasting plasma homocysteine levels are not associated with the increased risk of venous thromboembolic disease. *Blood Coagul Fibrinolysis* 2002;13:423-31.
- s17. Chango A, Potier De Courcy G, Boisson F, Guillard JC, Barbe F, Perrin MO, et al. 5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation en Vitamines et Mineraux Antioxydants (SU.VI.MAX) cohort. *Br J Nutr.* 2000;84:891-6.
- s18. Cappuccio FP, Bell R, Perry IJ, Gilg J, Ueland PM, Refsum H, et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. *Atherosclerosis.* 2002;164:95-102.
- s19. Castro R, Rivera I, Ravasco P, Jakobs C, Blom HJ, Camilo ME, et al. 5,10-Methylenetetrahydrofolate reductase 677C-->T and 1298A-->C mutations are genetic determinants of elevated homocysteine. *QJM.* 2003;96:297-303.
- s20. Chango A, Boisson F, Barbe F, Quilliot D, Droesch S, Pfister M, et al. The effect of 677C-->T and 1298A-->C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. *Br J Nutr.* 2000;83:593-6.
- s21. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. *Circulation.* 1996;94:2410-6.
- s22. Friedman G, Goldschmidt N, Friedlander Y, Ben-Yehuda A, Selhub J, Babaey S, et al. A common mutation A1298C in human methylenetetrahydrofolate reductase gene: association with plasma total homocysteine and folate concentrations. *J Nutr.* 1999;129:1656-61.
- s23. Husemoen LL, Thomsen TF, Fenger M, Jorgensen HL, Jorgensen T. Contribution of thermolabile methylenetetrahydrofolate reductase variant to total plasma homocysteine levels in healthy men and women. *Inter99 (2). Genet Epidemiol.* 2003;24:322-30.
- s24. Reyes-Engel A, Munoz E, Gaitan MJ, Fabre E, Gallo M, Dieguez JL, et al. Implications on human fertility of the 677C-->T and 1298A-->C polymorphisms of the MTHFR gene: consequences of a possible genetic selection. *Mol Hum Reprod.* 2002;8:952-7.
- s25. Schwartz SM, Siscovick DS, Malinow MR, Rosendaal FR, Beverly RK, Hess DL, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. *Circulation.* 1997;96:412-7.
- s26. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, et al. Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. *Arterioscler Thromb Vasc Biol.* 1997;17:569-73.
- s27. Meleady R, Ueland PM, Blom H, Whitehead AS, Refsum H, Daly LE, et al; EC Concerted Action Project: Homocysteine and Vascular Disease. Thermolabile methylenetetrahydrofolate reductase, homocysteine, and cardiovascular disease risk: the European Concerted Action Project. *Am J Clin Nutr.* 2003;77:63-70.
- s28. Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, Schneede J. Riboflavin as a determinant of plasma total homocysteine: effect modification by the methylenetetrahydrofolate reductase C677T polymorphism. *Clin Chem.* 2000;46:1065-71.
- s29. Yoo JH, Park SC. Low plasma folate in combination with the 677 C-->T methylenetetrahydrofolate reductase polymorphism is associated with increased risk of coronary artery disease in Koreans. *Thromb Res.* 2000;97:77-84.
- s30. Passaro A, Vanini A, Calzoni F, Alberti L, Zamboni PF, Fellin R, et al. Plasma homocysteine, methylenetetrahydrofolate reductase mutation and carotid damage in elderly healthy women. *Atherosclerosis.* 2001;157:175-80.
- s31. Pullin CH, Ashfield-Watt PA, Burr ML, Clark ZE, Lewis MJ, Moat SJ, et al. Optimization of dietary folate or low-dose folic acid supplements lower homocysteine but do not enhance endothelial

- function in healthy adults, irrespective of the methylenetetrahydrofolate reductase (C677T) genotype. *J Am Coll Cardiol.* 2001;38:1799-805.
- s32. Jee SH, Song KS, Shim WH, Kim HK, Suh I, Park JY, et al. Major gene evidence after MTHFR-segregation analysis of serum homocysteine in families of patients undergoing coronary arteriography. *Hum Genet.* 2002;111:128-35.
- s33. Litynski P, Loehrer F, Linder L, Todesco L, Fowler B. Effect of low doses of 5-methyltetrahydrofolate and folic acid on plasma homocysteine in healthy subjects with or without the 677C-->T polymorphism of methylenetetrahydrofolate reductase. *Eur J Clin Invest.* 2002;32:662-8.
- s34. de Bree A, Verschuren WM, Bjorke-Monsen AL, van der Put NM, Heil SG, Trijbels FJ, et al. Effect of the methylenetetrahydrofolate reductase 677C-->T mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample. *Am J Clin Nutr.* 2003;77:687-93.
- s35. Ou T, Yamakawa-Kobayashi K, Arinami T, Amemiya H, Fujiwara H, Kawata K, et al. Methylenetetrahydrofolate reductase and apolipoprotein E polymorphisms are independent risk factors for coronary heart disease in Japanese: a case-control study. *Atherosclerosis.* 1998;137:23-8.
- s36. Vizcaino G, Diez-Ewald M, Herrmann FH, Schuster G, Perez-Requejo JL. Relationships between homocysteine, folate and vitamin B12 levels with the methylenetetrahydrofolate reductase polymorphism, in Indians from Western Venezuela. *Thromb Haemost.* 2001;85:186-7.
- s37. D'Angelo A, Coppola A, Madonna P, Fermo I, Pagano A, Mazzola G, et al. The role of vitamin B12 in fasting hyperhomocysteinemia and its interaction with the homozygous C677T mutation of the methylenetetrahydrofolate reductase (MTHFR) gene. A case-control study of patients with early-onset thrombotic events. *Thromb Haemost.* 2000;83:563-70.
- s38. Zittoun J, Tonetti C, Bories D, Pignon JM, Tulliez M. Plasma homocysteine levels related to interactions between folate status and methylenetetrahydrofolate reductase: a study in 52 healthy subjects. *Metabolism.* 1998;47:1413-8.
- s39. Gemmati D, Previati M, Serino ML, Moratelli S, Guerra S, Capitani S, et al. Low folate levels and thermolabile methylenetetrahydrofolate reductase as primary determinant of mild hyperhomocystinemia in normal and thromboembolic subjects. *Arterioscler Thromb Vasc Biol.* 1999;19:1761-7.
- s40. Yingdong Z, Zhigang Z, Yang L. Association of plasma homocysteine level and N<sup>5</sup>, N<sup>10</sup>-methylenetetrahydrofolate reductase gene polymorphism with cerebral infarction. *Chinese Medical Sciences Journal.* 2002;17:231-5.
- s41. Varela ML, Adamczuk YP, Forastiero RR, Martinuzzo ME, Cerrato GS, Pombo G, et al. Major and potential prothrombotic genotypes in a cohort of patients with venous thromboembolism. *Thromb Res.* 2001;104:317-24.
- s42. Lalouschek W, Aull S, Korninger L, Mannhalter C, Pabinger-Fasching I, Schmid RW, et al. 677C to T mutation in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and plasma homocysteine levels in patients with TIA or minor stroke. *J Neurol Sci.* 1998;155:156-62.
- s43. Kim CH, Hwang KY, Choi TM, Shin WY, Hong SY. The methylenetetrahydrofolate reductase gene polymorphism in Koreans with coronary artery disease. *Int J Cardiol.* 2001;78:13-7.
- s44. Kosokabe T, Okumura K, Sone T, Kondo J, Tsuboi H, Mukawa H, et al. Relation of a common methylenetetrahydrofolate reductase mutation and plasma homocysteine with intimal hyperplasia after coronary stenting. *Circulation.* 2001;103:2048-54.
- s45. Dunn J, Title LM, Bata I, Johnstone DE, Kirkland SA, O'Neill BJ, et al. Relation of a common mutation in methylenetetrahydrofolate reductase to plasma homocysteine and early onset coronary artery disease. *Clin Biochem.* 1998;31:95-100.
- s46. Kluijtmans LA, Kastelein JJ, Lindemans J, Boers GH, Heil SG, Bruschke AV, et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. *Circulation.* 1997;96:2573-7.

- s47. Morita H, Kurihara H, Tsubaki S, Sugiyama T, Hamada C, Kurihara Y, et al. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke in Japanese. *Arterioscler Thromb Vasc Biol.* 1998;18:1465-9.
- s48. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, et al. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. *Circulation.* 2000;102:1227-32.
- s49. Deloughery TG, Evans A, Sadeghi A, McWilliams J, Henner WD, Taylor LM Jr, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. *Circulation.* 1996;94:3074-8.
- s50. Gaustadnes M, Rudiger N, Moller J, Rasmussen K, Bjerregaard Larsen T, Ingerslev J. Thrombophilic predisposition in stroke and venous thromboembolism in Danish patients. *Blood Coagul Fibrinolysis.* 1999;10:251-9.
- s51. Morelli VM, Lourenco DM, D'Almeida V, Franco RF, Miranda F, Zago MA, et al. Hyperhomocysteinemia increases the risk of venous thrombosis independent of the C677T mutation of the methylenetetrahydrofolate reductase gene in selected Brazilian patients. *Blood Coagul Fibrinolysis.* 2002;13:271-5.
- s52. Tokgozoglu SL, Alikasifoglu M, Unsal, Atalar E, Aytemir K, Ozer N, Ovunc K, Usal O, Kes S, Tuncbilek E. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. *Heart.* 1999;81:518-22.
- s53. Markus HS, Ali N, Swaminathan R, Sankaralingam A, Molloy J, Powell J. A common polymorphism in the methylenetetrahydrofolate reductase gene, homocysteine, and ischemic cerebrovascular disease. *Stroke.* 1997;28:1739-43.
- s54. Candito M, Bedoucha P, Gibelin P, Jambou D, de Franchis R, Sadoul JL, et al. Fasting, postprandial, and post-methionine-load homocysteinaemia and methylenetetrahydrofolate reductase polymorphism in vascular disease. *J Inherit Metab Dis.* 1999;22:588-92.
- s55. Andreassi MG, Botto N, Cocci F, Battaglia D, Antonioli E, Masetti S, et al. Methylenetetrahydrofolate reductase gene C677T polymorphism, homocysteine, vitamin B12, and DNA damage in coronary artery disease. *Hum Genet.* 2003;112:171-7.
- s56. Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, Baker RI. Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. *Stroke.* 2000;31:1069-75.
- s57. Nakata Y, Katsuya T, Takami S, Sato N, Fu Y, Ishikawa K, et al. Methylenetetrahydrofolate reductase gene polymorphism: relation to blood pressure and cerebrovascular disease. *Am J Hypertens.* 1998;11:1019-23.
- s58. Li Z, Sun L, Zhang H, Liao Y, Wang D, Zhao B, et al; Multicenter Case-Control Study in China. Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a Multicenter Case-Control Study in China. *Stroke.* 2003;34:2085-90.
- s59. Choi BO, Kim NK, Kim SH, Kang MS, Lee S, Ahn JY, et al. Homozygous C677T mutation in the MTHFR gene as an independent risk factor for multiple small-artery occlusions. *Thromb Res.* 2003;111:39-44.
- s60. Huang Y, Zhao YI Y, Li S. [Hyperhomocysteine, methylenetetrahydrofolate reductase gene, and other risk factors in ischemic stroke]. *Zhonghua Yi Xue Za Zhi.* 2002;82:119-22.
- s61. Kim NK, Choi BO, Jung WS, Choi YJ, Choi KG. Hyperhomocysteinemia as an independent risk factor for silent brain infarction. *Neurology.* 2003 Dec 9;61(11):1595-9.
- s62. Kohara K, Fujisawa M, Ando F, Tabara Y, Niino N, Miki T, et al; NILS-LSA Study. MTHFR gene polymorphism as a risk factor for silent brain infarcts and white matter lesions in the Japanese general population: The NILS-LSA Study. *Stroke.* 2003 May;34(5):1130-5.

- s63. Dikmen M, Ozbabalik D, Gunes HV, Degirmenci I, Bal C, Ozdemir G, Basaran A. Acute stroke in relation to homocysteine and methylenetetrahydrofolate reductase gene polymorphisms. *Acta Neurol Scand*. 2006 May;113(5):307-14.
- s64. Fang X, Namba H, Akamine S, Sugiyama K. Methylenetetrahydrofolate reductase gene polymorphisms in patients with cerebral hemorrhage. *Neurol Res*. 2005 Jan;27(1):73-6.
- s65. Fowkes FG, Lee AJ, Hau CM, Cooke A, Connor JM, Lowe GD. Methylene tetrahydrofolate reductase (MTHFR) and nitric oxide synthase (ecNOS) genes and risks of peripheral arterial disease and coronary heart disease: Edinburgh Artery Study. *Atherosclerosis*. 2000 May;150(1):179-85.
- s66. Frederiksen J, Juul K, Grande P, Jensen GB, Schroeder TV, Tybjaerg-Hansen A, Nordestgaard BG. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. *Blood*. 2004 Nov 15;104(10):3046-51.
- s67. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. *Brain*. 2004 Jan;127(Pt 1):212-9.
- s68. Kim OJ, Hong SP, Ahn JY, Hong SH, Hwang TS, Kim SO, Yoo W, Oh D, Kim NK. Influence of combined methionine synthase (MTR 2756A > G) and methylenetetrahydrofolate reductase (MTHFR 677C > T) polymorphisms to plasma homocysteine levels in Korean patients with ischemic stroke. *Yonsei Med J*. 2007 Apr 30;48(2):201-9.
- s69. Miyaki K, Omae K, Murata M, Tanahashi N, Saito I, Watanabe K. High throughput multiple combination extraction from large scale polymorphism data by exact tree method. *J Hum Genet*. 2004;49(9):455-62.
- s70. Pezzini A, Grassi M, Del Zotto E, Assanelli D, Archetti S, Negrini R, Caimi L, Padovani A. Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotype-disease analysis and genotype-disease analysis. *J Neurol Neurosurg Psychiatry*. 2006 Oct;77(10):1150-6.
- s71. Slooter AJ, Rosendaal FR, Tanis BC, Kemmeren JM, van der Graaf Y, Algra A. Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. *J Thromb Haemost*. 2005 Jun;3(6):1213-7.
- s72. Miller GJ, Bauer KA, Barzegar S, et al. The effects of quality and timing of venepuncture on markers of blood coagulation in healthy middle-aged men. *Thromb Haemost* 1995;73:82-6. Unpublished data from Northwick Park Heart Study II (Hcy and stroke)
- s73. Shmeleva, Kasputin S. Genetic polymorphisms and environmental influences in arterial occlusive diseases. *Journal of Thrombosis and Haemostasis*. 2005;3(Suppl 1): Abstract number: P2273.
- s74. Kim IG, Kim JT, Kim MK. Methylenetetrahydrofolate reductase gene single nucleotide polymorphism in korean population with ischemic stroke. *Chonnam Medical Journal* 2007;43:25-32
- s75. Panigrahi I, Chatterjee T, Biswas A, Behari M, Choudhry PV, Saxena R. Role of MTHFR C677T polymorphism in ischemic stroke. *Neurol India*. 2006 Mar;54(1):48-50. Unpublished data (Hcy and stroke)\_
- s76. Karakus Z, Gurkan E. *Annals of Medical Sciences*. 2005; 14(3):31-36
- s77. Zee RY, Mora S, Cheng S, Erlich HA, Lindpaintner K, Rifai N, Buring JE, Ridker PM. Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women. *Clin Chem*. 2007 May;53(5):845-51.
- s78. Linnebank M, Moskau S, Farmand S, Fliessbach K, Kölsch H, Bös M, Grothe C, Becker D, Harbrecht U, Pohl C, Wüllner U, Klockgether T. Homocysteine and carotid intima-media thickness in a german population: lack of clinical relevance. *Stroke*. 2006 Nov;37(11):2840-2.

- s79. Marcucci R, Sofi F, Fedi S, Lari B, Sestini I, Cellai AP, Pulli R, Pratesi G, Pratesi C, Gensini GF, Abbate R. Thrombophilic risk factors in patients with severe carotid atherosclerosis. *J Thromb Haemost.* 2005 Mar;3(3):502-7.
- s80. Motti C, Gnasso A, Bernardini S, Massoud R, Pastore A, Rampa P, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine and other risk factors for vascular disease. *Atherosclerosis.* 1998;139:377-83.
- s81. Rothenbacher D, Fischer HG, Hoffmeister A, Hoffmann MM, Marz W, Bode G, et al. Homocysteine and methylenetetrahydrofolate reductase genotype: association with risk of coronary heart disease and relation to inflammatory, hemostatic, and lipid parameters. *Atherosclerosis.* 2002;162:193-200.
- s82. Todesco L, Angst C, Litynski P, Loehrer F, Fowler B, Haefeli WE. Methylenetetrahydrofolate reductase polymorphism, plasma homocysteine and age. *Eur J Clin Invest.* 1999;29:1003-9.
- s83. Verhoef P, Kok FJ, Kluijtmans LA, Blom HJ, Refsum H, Ueland PM, et al. The 677C-->T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. *Atherosclerosis.* 1997;132:105-13.
- s84. Verhoeff BJ, Trip MD, Prins MH, Kastelein JJ, Reitsma PH. The effect of a common methylenetetrahydrofolate reductase mutation on levels of homocysteine, folate, vitamin B12 and on the risk of premature atherosclerosis. *Atherosclerosis.* 1998;141:161-6.
- s85. Ashfield-Watt PA, Pullin CH, Whiting JM, Clark ZE, Moat SJ, Newcombe RG, et al. Methylenetetrahydrofolate reductase 677C-->T genotype modulates homocysteine responses to a folate-rich diet or a low-dose folic acid supplement: a randomized controlled trial. *Am J Clin Nutr.* 2002;76:180-6.
- s86. Pullin CH, Wilson JF, Ashfield-Watt PA, Clark ZE, Whiting JM, Lewis MJ, et al. Influence of methylenetetrahydrofolate reductase genotype, exercise and other risk factors on endothelial function in healthy individuals. *Clin Sci (Lond).* 2002;102:45-50.
- s87. Trinh BN, Ong CN, Coetzee GA, Yu MC, Laird PW. Thymidylate synthase: a novel genetic determinant of plasma homocysteine and folate levels. *Hum Genet.* 2002;111:299-302.
- s88. Saw SM, Yuan JM, Ong CN, Arakawa K, Lee HP, Coetzee GA, et al. Genetic, dietary, and other lifestyle determinants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. *Am J Clin Nutr.* 2001;73:232-9.
- s89. Mager A, Battler A, Birnbaum Y, Magal N, Shohat M. Plasma homocysteine, methylenetetrahydrofolate reductase genotypes, and age at onset of symptoms of myocardial ischemia. *Am J Cardiol.* 2002;89:919-23.
- s90. Soriente L, Coppola A, Madonna P, Cerbone AM, Di Minno G, Orefice G, et al. Homozygous C677T mutation of the 5,10 methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in Italian patients with a history of early-onset ischemic stroke. *Stroke.* 1998;29:869-71.
- s91. Morita H, Taguchi J, Kurihara H, Kitaoka M, Kaneda H, Kurihara Y, et al. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. *Circulation.* 1997;95:2032-6.
- s92. Grossmann R, Geisen U, Merati G, Mullges W, Schambeck CM, Walter U, et al. Genetic risk factors in young adults with 'cryptogenic' ischemic cerebrovascular disease. *Blood Coagul Fibrinolysis.* 2002;13:583-90.
- s93. Reuner KH, Ruf A, Kaps M, Druschky KF, Patscheke H. The mutation C677-->T in the methylene tetrahydrofolate reductase gene and stroke. *Thromb Haemost.* 1998;79:450-1.
- s94. Zhang G, Dai C. Gene polymorphisms of homocysteine metabolism-related enzymes in Chinese patients with occlusive coronary artery or cerebral vascular diseases. *Thromb Res.* 2001;104:187-95.

- s95. Yoo JH, Choi GD, Kang SS. Pathogenicity of thermolabile methylenetetrahydrofolate reductase for vascular dementia. *Arterioscler Thromb Vasc Biol.* 2000;20:1921-5.
- s96. Zheng YZ, Tong J, Do XP, Pu XQ, Zhou BT. Prevalence of methylenetetrahydrofolate reductase C677T and its association with arterial and venous thrombosis in the Chinese population. *Br J Haematol.* 2000;109:870-4.
- s97. Salooja N, Catto A, Carter A, Tudenham EG, Grant PJ. Methylene tetrahydrofolate reductase C677T genotype and stroke. *Clin Lab Haematol.* 1998;20:357-361.
- s98. Kostulas K, Crisby M, Huang WX, Lannfelt L, Hagenfeldt L, Eggertsen G, et al. A methylenetetrahydrofolate reductase gene polymorphism in ischaemic stroke and in carotid artery stenosis. *Eur J Clin Invest.* 1998;28:285-9.
- s99. Lopaciuk S, Bykowska K, Kwiecinski H, Mickielewicz A, Czlonkowska A, Mendel T, et al. Factor V Leiden, prothrombin gene G20210A variant, and methylenetetrahydrofolate reductase C677T genotype in young adults with ischemic stroke. *Clin Appl Thromb Hemost.* 2001;7:346-50.
- s100. Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Lang T, et al. Genetic and nongenetic factors influencing plasma homocysteine levels in patients with ischemic cerebrovascular disease and in healthy control subjects. *J Lab Clin Med.* 1999;133:575-82.
- s101. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinari M, et al. Prothrombin G20210A mutant genotype is a risk factor for cerebrovascular ischemic disease in young patients. *Blood.* 1998;91:3562-5.
- s102. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bene J, et al. Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. *J Neurol Neurosurg Psychiatry.* 2003;74:1615-20.
- s103. Notsu Y, Nabika T, Park HY, Masuda J, Kobayashi S. Evaluation of genetic risk factors for silent brain infarction. *Stroke.* 1999;30:1881-6.
- s104. Voetsch B, Damasceno BP, Camargo EC, Massaro A, Bacheschi LA, Scaff M, et al. Inherited thrombophilia as a risk factor for the development of ischemic stroke in young adults. *Thromb Haemost.* 2000;83:229-33.
- s105. Margaglione M, D'Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E, et al. Inherited prothrombotic conditions and premature ischemic stroke: sex difference in the association with factor V Leiden. *Arterioscler Thromb Vasc Biol.* 1999;19:1751-6.
- s106. Pezzini A, Del Zotto E, Magoni M, Costa A, Archetti S, Grassi M, et al. Inherited thrombophilic disorders in young adults with ischemic stroke and patent foramen ovale. *Stroke.* 2003;34:28-33.
- s107. Harmon DL, Doyle RM, Meleady R, Doyle M, Shields DC, Barry R, et al. Genetic analysis of the thermolabile variant of 5, 10-methylenetetrahydrofolate reductase as a risk factor for ischemic stroke. *Arterioscler Thromb Vasc Biol.* 1999;19:208-11.
- s108. Kristensen B, Malm J, Nilsson TK, Hulldin J, Carlberg B, Dahlen G, et al. Hyperhomocysteinemia and hypofibrinolysis in young adults with ischemic stroke. *Stroke.* 1999;30:974-80.
- s109. Pezzini A, Del Zotto E, Archetti S, Negrini R, Bani P, Albertini A, et al. Plasma homocysteine concentration, C677T MTHFR genotype, and 844ins68bp CBS genotype in young adults with spontaneous cervical artery dissection and atherothrombotic stroke. *Stroke.* 2002;33:664-9.
- s110. Wu Y, Tomon M, Sumino K. Methylenetetrahydrofolate reductase gene polymorphism and ischemic stroke: sex difference in Japanese. *Kobe J Med Sci.* 2001;47:255-62.
- s111. Press RD, Beamer N, Evans A, DeLoughery TG, Coull BM. Role of a common mutation in the homocysteine regulatory enzyme methylenetetrahydrofolate reductase in ischemic stroke. *Diagn Mol Pathol.* 1999;8:54-8.
- s112. Topic E, Timundic AM, Ttefanovic M, Demarin V, Vukovic V, Lovrencic-Huzjan A, et al. Polymorphism of apoprotein E (APOE), methylenetetrahydrofolate reductase (MTHFR) and paraoxonase (PON1) genes in patients with cerebrovascular disease. *Clin Chem Lab Med.* 2001;39:346-50.



- s113. Pongracz E, Tordai A, Csornai M, Nagy Z. [Genetics of blood coagulation in young stroke patients]. *Ideggyogy Sz.* 2002;55:111-7.
- s114. Li C, Zhang C, Qiu S, Lu X, Zeng Y, Wu H, et al. Polymorphisms of ACE-1 and MTHFR genes and genetic susceptibility of ischemic stroke. *Zhonghua Yi Xue Za Zhi.* 2002;82:1046-9.
- s115. Duca F, Sacchi E, Tagliabue L, Tajoli E. C677T methylenetetrahydrofolate reductase (MTHFR) mutation in stroke [Abstract]. *Thromb Haemost.* 1997;78(suppl):102.
- s116. Gross B, Antebi A, Cassel A, Honigman S. Is a mutation in the enzyme MTHFR a risk factor for stroke in young adults? [Abstract]. *Neurology.* 2000;54:(suppl 3):142.
- s117. De Stefano V, Chiusolo P, Casorelli I, et al. Inborn putative causes of mild hyperhomocysteinemia and risk for ischemic stroke in the young. [Abstract]. *Thromb Haemost* 2001;85(suppl):P2266.
- s118. Pratick M, Lewandowski L, Lukasik M, et al. High frequency of combined genetic prothrombotic defects in young patients with ischemic stroke. [Abstract]. *Journal of Thrombosis and Haemostasis* 2003;1(suppl 1):P0995
- s119. Kalashnikova L, Patrusheva L, Kovalenko T, Dobrynina L, Alexandrova E, Nassonov E. Factor V Leiden, prothrombin G20210A, and MTHFR/C677T gene mutations in patients with primary anti-phospholipid syndrome and cerebrovascular disorder.[Abstract]. *Journal of Thrombosis and Haemostasis* 2003;1(suppl 1):P0994
- s120. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L. Evaluation of the interactions of common genetic mutations in stroke subtypes. *J Neurol.* 2002;249:1391-7.
- s121. Lalouschek W, Aull S, Serles W, Schnider P, Mannhalter C, Pabinger-Fasching I, et al. C677T MTHFR mutation and factor V Leiden mutation in patients with TIA/minor stroke: a case-control study. *Thromb Res.* 1999;93:61-9.
- s122. Morita H, Kurihara H, Sugiyama T, Kitamura K, Suzuki S, Sumiyoshi T, et al. [Genetic polymorphisms of methylenetetrahydrofolate reductase and methionine synthase: association with homocysteine metabolism and late-onset vascular diseases in the Japanese population]. *J Cardiol.* 1999;33:106-7.
- s123. Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J. Paraoxonase 192 Gln-->Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. *Stroke.* 2002;33:1459-64.
- s124. Kelly PJ, Shih VE, Kistler JP, Barron M, Lee H, Mandell R, et al. Low vitamin B6 but not homocysteine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. *Stroke.* 2003;34:e51-4.
- s125. Madonna P, de Stefano V, Coppola A, Cirillo F, Cerbone AM, Orefice G, et al. Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. *Stroke.* 2002;33:51-6.
- s126. Austin H, Chimowitz MI, Hill HA, Chaturvedi S, Wechsler LR, Wityk RJ, et al; Genetics and Stroke in the Young Study Group. Cryptogenic stroke in relation to genetic variation in clotting factors and other genetic polymorphisms among young men and women. *Stroke.* 2002 Dec;33(12):2762-8.
- s127. Alluri RV, Mohan V, Komandur S, Chawda K, Chaudhuri JR, Hasan Q. MTHFR C677T gene mutation as a risk factor for arterial stroke: a hospital based study. *Eur J Neurol.* 2005;12(1):40-4.
- s128. Bosco P, Guéant-Rodriguez RM, Anello G, Spada R, Romano A, Fajardo A, Caraci F, Ferri R, Guéant JL. Association of homocysteine (but not of MTHFR 677 C>T, MTR 2756 A>G, MTRR 66 A>G and TCN2 776 C>G) with ischaemic cerebrovascular disease in Sicily. *Thromb Haemost.* 2006 Aug;96(2):154-9.
- s129. Hermans MP, Gala JL, Buysschaert M. The MTHFR CT polymorphism confers a high risk for stroke in both homozygous and heterozygous T allele carriers with Type 2 diabetes. *Diabet Med.* 2006 May;23(5):529-36.

- s130. Lewis SJ, Lawlor DA, Davey Smith G, Araya R, Timpson N, Day IN, Ebrahim S. The thermolabile variant of MTHFR is associated with depression in the British Women's Heart and Health Study and a meta-analysis. *Mol Psychiatry*. 2006 Apr;11(4):352-60. Unpublished data (stroke)\_
- s131. Ye H, Yan JT, Shao JM, Zhang F, Hong ML, Wang DW. [A case-control study on the relationship between stroke and plasma homocysteine level and the mutation of MTHFR gene.] *Zhonghua Liu Xing Bing Xue Za Zhi*. 2004 Nov;25(11):958-61.
- s132. Baum L, Wong KS, Ng HK, Tomlinson B, Rainer TH, Chan DK, Thomas GN, Chen X, Poon P, Cheung WS, Woo KS. Methylenetetrahydrofolate reductase gene A222V polymorphism and risk of ischemic stroke. *Clin Chem Lab Med*. 2004;42(12):1370-6.
- s133. Boncoraglio G, Carriero MR, Chiapparini L, Ciceri E, Ciusani E, Erbetta A, Parati EA. Hyperhomocysteinemia and other thrombophilic risk factors in 26 patients with cerebral venous thrombosis. *Eur J Neurol*. 2004 Jun;11(6):405-9.
- s134. Gutiérrez JI, Pérez F, Tamparillas M, Grasa JM, Calvo MT, Osuna C, Sánchez B, Torres M. [Polymorphisms in cystathionine beta-synthase and methylenetetrahydrofolate reductase genes as risk factors for cerebral vascular disease]. *Med Clin (Barc)*. 2005 Mar 5;124(8):281-4.
- s135. Kawamoto R, Kohara K, Tabara Y, Miki T, Doi T, Tokunaga H, Konishi I. An association of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene polymorphism and common carotid atherosclerosis. *J Hum Genet*. 2001;46(9):506-10.
- s136. Lalouschek W, Endler G, Schillinger M, Hsieh K, Lang W, Cheng S, Bauer P, Wagner O, Mannhalter C. Candidate genetic risk factors of stroke: results of a multilocus genotyping assay. *Clin Chem*. 2007 Apr;53(4):600-5.
- s137. Linnebank M, Montenarh M, Kölsch H, Linnebank A, Schnez K, Schweichel D, Pohl C, Urbach H, Heun R, Harbrecht U, Klockgether T, Wüllner U. Common genetic variants of homocysteine metabolism in ischemic stroke: a case-control study. *Eur J Neurol*. 2005 Aug;12(8):614-8.
- s138. Pezzini A, Grassi M, Del Zotto E, Archetti S, Spezi R, Vergani V, Assanelli D, Caimi L, Padovani A. Cumulative effect of predisposing genotypes and their interaction with modifiable factors on the risk of ischemic stroke in young adults. *Stroke*. 2005 Mar;36(3):533-9.
- s139. Pezzini A, Grassi M, Iacoviello L, Del Zotto E, Archetti S, Giossi A, Padovani A. Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives. *J Neurol Neurosurg Psychiatry*. 2007 Mar;78(3):271-6.
- s140. Roest M, van der Schouw YT, Grobbee DE, Tempelman MJ, de Groot PG, Sixma JJ, Banga JD. Methylenetetrahydrofolate reductase 677 C/T genotype and cardiovascular disease mortality in postmenopausal women. *Am J Epidemiol*. 2001 Apr 1;153(7):673-9.
- s141. Sánchez-Marín B, Grasa JM, Torres M, Calvo MT, Martínez-Jarreta B, García-Erce JA, Giralt M. [Prevalence of methylenetetrahydrofolate reductase C677T mutation among patients with acute ischemic cerebrovascular disease in Aragon] *An Med Interna*. 2006 Apr;23(4):153-5.
- s142. Sazci A, Ergul E, Tuncer N, Akpınar G, Kara I. Methylenetetrahydrofolate reductase gene polymorphisms are associated with ischemic and hemorrhagic stroke: Dual effect of MTHFR polymorphisms C677T and A1298C. *Brain Res Bull*. 2006 Dec 11;71(1-3):45-50.
- s143. Szolnoki Z, Havasi V, Bene J, Komlósi K, Szöke D, Somogyvári F, Kondacs A, Szabó M, Fodor L, Bodor A, Gáti I, Wittman I, Melegh B. Endothelial nitric oxide synthase gene interactions and the risk of ischaemic stroke. *Acta Neurol Scand*. 2005 Jan;111(1):29-33.
- s144. Szolnoki Z, Somogyvári F, Szabó M, Kondacs A, Fodor L, Melegh B. [Interactions between the MTHFR C677T and MTHFR A1298C mutations in ischaemic stroke] *Ideggyogy Sz*. 2006 Mar 20;59(3-4):107-12.
- s145. Uçar F, Sönmez M, Ovalı E, Özmenoglu M, Kartı SS, Yılmaz M, Pakdemir A. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. *Am J Hematol*. 2004 May;76(1):40-3.

- s146. Voetsch B, Benke KS, Panhuysen CI, Damasceno BP, Loscalzo J. The combined effect of paraoxonase promoter and coding region polymorphisms on the risk of arterial ischemic stroke among young adults. *Arch Neurol*. 2004 Mar;61(3):351-6.
- s147. Gao X, Yang H, ZhiPing T. Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. *Neurosci Lett*. 2006 May 8;398(3):172-7.
- s148. Yamada Y, Metoki N, Yoshida H, Satoh K, Ichihara S, Kato K, Kameyama T, Yokoi K, Matsuo H, Segawa T, Watanabe S, Nozawa Y. Genetic risk for ischemic and hemorrhagic stroke. *Arterioscler Thromb Vasc Biol*. 2006 Aug;26(8):1920-5.
- s149. Kostulas K, Brophy VH, Moraitis K, Manolescu A, Kostulas V, Gretarsdottir S, Cheng S, Hillert J. Genetic profile of ischemic cerebrovascular disease and carotid stenosis. *Acta Neurol Scand*. 2008 Sep;118(3):146-52.
- s150. Semmler A, Linnebank M, Krex D, Götz A, Moskau S, Ziegler A, Simon M. Polymorphisms of homocysteine metabolism are associated with intracranial aneurysms. *Cerebrovasc Dis*. 2008;26(4):425-9.
- s151. Fang L, Wu YQ, Wang TW. Correlations of polymorphism of methylenetetrahydrofolate reductase and cystathionine beta-synthase genes with heredity of cerebral infarction and cerebral hemorrhage in northern Chinese Han people. *Zhongguo Linchuang Kangfu* (2004), 8(22), 4654-4656.
- s152. Gao HF, Liu JG, Zhang ZC, et al. The relationship between hyperhomocysteinemia and MTHFR gene in young adult cerebral infarction patients. *Tian Jin Yi Yao*. 2003;10:627-629
- s153. Li YJ, Huo Y, Gao XG, et al. A statistical study on the relationship between gene polymorphism of b-fibrinogen -148C/T, N5,N10-methylene tetrahydrofolic acid reductase 677C/T and cerebral infarction. *Zhong Guo Shen Jing Mian Yi Xue He Shen Jing Bing Xue Za Zhi*. 2005;12:363-367.
- s154. Qin MZ, Qin YZ. Correlation between Hcy and polymorphism of gene methylenetetrahydrofolate reductase and ischemic cerebral stroke. *Zhing Guo Mei Tan Gong Ye Yi Xue Za Zhi*. 2005;8:474-475.
- s155. Sun WP, Wan Qi, Su MQ. Genetic polymorphism of 5,10-methylenetetrahydrofolate reductase (MTHFR) in patients with cerebral infarction. *Zhong Hua Lao Nian Xin Nao Xue Guan Bing Za Zhi*. 2003;5:36-38.
- s156. Teng L, Zhao YB, Wang XC, et al. Relation between MTHFR gene polymorphism and arteriosclerotic cerebral infarction. *Yi Chuan*. 1999; 21:13-16.
- s157. Tu CQ, Huang MQ, Wu JZ, et al. The relation of methylenetetrahydrofolate reductase gene mutation and cystathionine B-synthase gene mutation exist in cerebral infarction. *Xue Shuan Yu Zhi Xue Xue*. 2002; 8:149-151.
- s158. Xiao YQ, Jiang LL, Lu Q, et al. Relationship between gene polymorphism of methylenetetrahydrofolate reductase and plasma homocysteine level with cerebrovascular disease. *Jian Yan Yi Xue*. 2006;21:201-204.
- s159. Zhang YD, Zhu ZG, Liu Y. The association of plasma Hcy level and MTHFR gene polymorphism with cerebral infarction. *Zhong Feng Yu Shen Jing Ji Bing Za Zhi*. 2001; 18:198-200
- s160. Zhang Y, Xie RP, Wang YH, et al. Study about association between MTHFR gene polymorphism and cerebral infarction. *Zhong Hua Shen Jing Ke Za Zhi*. 2003; 36:73-74.
- s161. Fang L. et al. *Journal of Jilin University (Medicine Edition)*. 2007; 33(2):310-313
- s162. Mcllroy SP, Dynan KB, Lawson JT, Patterson CC, Passmore AP. Moderately elevated plasma homocysteine, methylenetetrahydrofolate reductase genotype, and risk for stroke, vascular dementia, and Alzheimer disease in Northern Ireland. *Stroke*. 2002;33:2351-6.
- s163. Li CM, et al. *Chin Crit Care Med*. 2006; 18(5):264-267
- s164. Nan GX, et al. *Chinese Journal of Clinical Rehabilitation*. 2006; 10(4):184-186

- s165. NG KM, et al. *Hereditas* (Beijing). 2004; 26(3):298-302
- s166. Gadelha TB, Nogueira MA, Nucci M. Thrombophilic predisposition to ischemic stroke in Brazilian young adults. *Thrombosis and Haemostasis*. 2001 (suppl) P2202 (abstr.).
- s167. Toulon P, Zuber M, Mas JL. Genetic polymorphisms and the risk of development of ischemic stroke. Results of a case control study. *Journal of Thrombosis and Haemostasis*. 2003;1(Suppl 1): Abstract P0998.
- s168. Uçar F, Sönmez M, Ovali E, Ozmenoglu M, Karti SS, Yilmaz M, Pakdemir A. MTHFR C677T polymorphism and its relation to ischemic stroke in the Black Sea Turkish population. *Am J Hematol*. 2004 May;76(1):40-3.
- s169. Moskau S, Smolka K, Semmler A, Schweichel D, Harbrecht U, Müller J, Pohl C, Klockgether T, Linnebank M. Common genetic coagulation variants are not associated with ischemic stroke in a casecontrol study. *Neurol Res*. 2009 Aug 5. [Epub ahead of print]
- s170. Gao X, Yang H, ZhiPing T: Association studies of genetic polymorphism, environmental factors and their interaction in ischemic stroke. *Neurosci Lett* 2006;398:172-177
- s171. Sánchez-Marín B, Grasa JM, Torres M, Calvo MT, Martínez-Jarreta B, García-Erce JA, Giralt M. Prevalence of methylenetetrahydrofolate reductase C677T mutation among patients with acute ischemic cerebrovascular disease in Aragon. *An Med Interna*. 2006 Apr;23(4):153-5.
- s172. Marie SK, Shinjo SK, Oba-Shinjo SM, da Silva R, Barbosa KC, Yamamoto F, Scaff M. Methylenetetrahydrofolate reductase gene polymorphism is not related to the risk of ischemic cerebrovascular disease in a Brazilian population. *Clinics (Sao Paulo)*. 2007 Jun;62(3):295-300.
- s173. Moe KT, Woon FP, De Silva DA, Wong P, Koh TH, Kingwell B, Chin-Dusting J, Wong MC. Association of acute ischemic stroke with the MTHFR C677T polymorphism but not with NOS3 gene polymorphisms in a Singapore population. *Eur J Neurol*. 2008 Dec;15(12):1309-14.
- s174. Hofman A, Breteler MM, van Duijn CM, Janssen HL, Krestin GP, Kuipers EJ, Stricker BH, Tiemeier H, Uitterlinden AG, Vingerling JR, Witteman JC. The Rotterdam Study: 2010 objectives and design update. *Eur J Epidemiol*. 2009;24(9):553-72. Unpublished data (stroke)
- s175. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. *European Prospective Investigation of Cancer*. *Br J Cancer*. 1999 Jul;80 Suppl 1:95-103. Unpublished data (stroke)
- s176. Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A, Pikhart H, Nicholson A, Marmot M. Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. *BMC Public Health*. 2006 Oct 18;6:255. Unpublished data (Hcy)
- s177. Weikert C, Dierkes J, Hoffmann K, Berger K, Drogan D, et al. B Vitamin Plasma Levels and the Risk of Ischemic Stroke and Transient Ischemic Attack in a German Cohort. *Stroke* 2007;38;2912-2918
- s178. Somarajan BI, Kalita J, Mittal B, Misra UK. Evaluation of MTHFR C677T polymorphism in ischemic and hemorrhagic stroke patients. A case-control study in a Northern Indian population. *J Neurol Sciences* 2011;304(1-2):67-70
- s179. ISGS-SWISS: Meschia JF, Brott TG, Brown RD, Jr., Crook RJ, Frankel M, Hardy J, et al. The Ischemic Stroke Genetics Study (ISGS) Protocol. *BMC Neurol*. 2003 Jul 8;3:4 and Meschia JF, Brown RD, Jr., Brott TG, Chukwudelunzu FE, Hardy J, Rich SS. The Siblings With Ischemic Stroke Study (SWISS) protocol. *BMC Med Genet*. 2002;3:1. Unpublished data (stroke)
- s180. Norman PE, Flicker L, Almeida OP, Hankey GJ, Hyde Z, Jamrozik K. Cohort Profile: The Health In Men Study (HIMS). *Int J Epidemiol*. 2009 Feb;38(1):48-52. Unpublished data (stroke)